News tagged with doxorubicin
Magnetic nanochain detonates chemo barrage inside tumors
Medicine-toting nanochains slip into tumors and explode a chemotherapy drug into hard-to-reach cores of cancer, engineers and scientists at Case Western Reserve University report.
Nanotechnology / Bio & Medicine
Apr 18, 2012 |
5 / 5 (8) |
0
|
Overcoming cancer drug resistance with nanoparticles
One of the ways in which cancer cells evade anticancer therapy is by producing a protein that pumps drugs out of the cell before these compounds can exert their cell-killing effects. A research team at Northwestern University ...
Nanotechnology / Bio & Medicine
Jan 20, 2012 |
5 / 5 (2) |
0
|
Inhaled nanoparticles deliver potent anticancer cocktail to lung tumors and block resistance
(PhysOrg.com) -- An ideal treatment for lung cancer would be one that could be inhaled deep into lung tissue where it would deliver tumor-killing agents that would then largely stay in the lungs, avoiding the toxicities that ...
Nanotechnology / Bio & Medicine
Nov 21, 2011 |
4.8 / 5 (4) |
0
|
Therapeutic nanoparticles targeted to radiation treated tumors
Radiation and chemotherapy are common partners in anticancer therapy for solid tumors, but too often, the combined side effects associated with each mode of therapy can limit how aggressively oncologists can treat their patients. ...
Nanotechnology / Bio & Medicine
Mar 28, 2011 |
not rated yet |
0
|
Nanodiamonds take big step toward battling cancer
Chemotherapy drug resistance contributes to treatment failure in more than 90 percent of metastatic cancers. Overcoming this hurdle would significantly improve cancer survival rates.
Nanotechnology / Bio & Medicine
Mar 09, 2011 |
5 / 5 (3) |
0
|
Nanoparticles deliver one-two therapeutic punch to kill tumor cells
The standard approach to cancer therapy today is to mix and match chemotherapy drugs in order to attack tumors in multiple ways. Now, two separate teams of investigators have demonstrated that using nanoparticles to deliver ...
Nanotechnology / Bio & Medicine
Dec 17, 2010 |
4.9 / 5 (7) |
1
|
Cancer scientists believe nanoparticles could accurately target tumors, avoiding side effects
In the past 40 years, scientists have learned a great deal about how cells become cancerous. Some of that knowledge has translated to new treatments, but most of the time doctors are forced to rely on standard ch ...
Nanotechnology / Bio & Medicine
Nov 18, 2010 |
5 / 5 (3) |
1
|
Combination therapy improves survival time for patients with advanced liver cancer
Treatment of inoperable advanced liver cancer with the agent doxorubicin (routinely used to treat this condition) in addition to the agent sorafenib resulted in greater overall survival and progression-free survival, compared ...
Nov 16, 2010 |
not rated yet |
0
New treatment approach to rare cancer results in prolonged survival
Aggressive treatment of anaplastic thyroid carcinoma has dramatically increased survival in the small group of patients who chose to undergo it, say physicians at Mayo Clinic. Their findings will be presented at the annual ...
May 26, 2010 |
5 / 5 (1) |
0
Two-In-One Punch Knocks Out Drug Resistant Cancer Cells
(PhysOrg.com) -- Cancer cells, like bacteria, can develop resistance to drug therapy, leading to relapse of disease. One approach showing promise in overcoming multidrug resistance in tumors is to combine two different anticancer ...
Nanotechnology / Bio & Medicine
Nov 04, 2009 |
5 / 5 (4) |
0
Gene alterations associated with response to anthracycline therapy for breast cancer
Alterations in the topoisomerase II alpha (TOP2A) gene were associated with better patient outcomes following anthracycline-based therapy compared with non-anthracycline-based regimens, according to a study in the April ...
Apr 28, 2009 |
not rated yet |
0
Light scattering technology may hold promise for quickly determining chemotherapy's effectiveness
By examining the patterns in which light bounces off cell surfaces, researchers may be able to assess chemotherapy's success in inducing cancer cell death, according to a study led by investigators in the Duke Comprehensive ...
Apr 21, 2009 |
not rated yet |
0
Microfluidic Device Mimics Tumor Microenvironment, Helps Drug Discovery Efforts
One of the challenges that cancer researchers face in designing new antitumor agents is that of predicting how drug molecules will behave in the complex microenvironment that surrounds a tumor. In particular, tumors create ...
Feb 23, 2009 |
not rated yet |
1
Doxorubicin
Doxorubicin INN ( /ˌdɒksəˈruːbəsɪn/; trade name Adriamycin; also known as hydroxydaunorubicin) is a drug used in cancer chemotherapy. It is an anthracycline antibiotic, closely related to the natural product daunomycin, and like all anthracyclines, it works by intercalating DNA.
Doxorubicin is commonly used in the treatment of a wide range of cancers, including hematological malignancies, many types of carcinoma, and soft tissue sarcomas.
Doxorubicin's most serious adverse effect is life-threatening heart damage.
The drug is administered intravenously, in the form of hydrochloride salt. It may be sold under the brand names Adriamycin PFS, Adriamycin RDF, or Rubex. Doxorubicin is photosensitive, and containers are often covered by an aluminum bag and/or brown wax paper to prevent light from affecting it.
The molecule was originally isolated in the 1950s from bacteria found in soil samples taken from Castel del Monte, an Italian castle.
For more information about Doxorubicin, read the full article at
Wikipedia.
This text uses material from Wikipedia and is available under the GNU Free Documentation License.
